Mabcure, Inc. Featured in BioWorld® Today

MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the June 4, 2009 edition of BioWorld® Today, biotech’s most respected news source for over seventeen years.

The cover story, written by Jennifer Boggs and titled “MabCure’s Revamped Hybridoma Approach Seeks Cancer Antigens,” describes the company’s “new take on a classic drug discovery technology,” detailing how MabCure is developing monoclonal antibodies against difficult-to-pinpoint tumor specific antigens (TSA) for the diagnostics market. In the article Dr. Amnon Gonenne, the company’s president and CEO, explained that while cancer is 90-95% curable if caught early, the challenge in early detection lies in the lack of clearly identified cancer markers.

Highlighted in the piece is MabCure’s proof of concept which came in melanoma “…where scientists selected about half a dozen antibodies from ‘tens of thousands’ that are highly specific to melanoma –with no cross-reaction to predecessor melanoma cells –for in vitro testing.” That large pool of antibodies necessary to draw out those highly specific antibodies to melanoma was created using MabCure’s proprietary re-engineered hybridoma technology, which can produce 10,000-20,000 antibodies in just four-to-six weeks. By way of comparison, classic hybridoma technology is relatively inefficient, producing around 1,000 antibodies in four-to-six months. Recombinant technology is favored to classic hybridoma for its efficiency, but it generally requires the knowledge of the antigens, which in the case of cancer, has been elusive. In addition, it is unable to make antibodies to sugar-coated antigens which is often the case for cell surface proteins (antigens), and cancer cells in particular. MabCure’s unique approach offers the best of both processes, one that is both efficient and highly specific. Regarding the success of this proof of concept, Dr. Gonenne said “. . . the theory was that the antibodies would recognize any type of melanoma cell, and researchers proved it by successfully testing them against ocular melanoma tissue.” The anti-melanoma antibodies were able to recognize both advance and early disease of the eye suggesting that the MabCure technology could potentially generate antibodies that can recognize early disease in other cancers as well.

The article went on to note that MabCure is gearing up for clinical testing in prostate and ovarian cancers and that the company intends to seek a commercial partner in the diagnostic field for those programs.

“We are delighted to receive coverage of this caliber in a publication as venerable as BioWorld Today,” says Dr. Gonenne. “Media stories such as this afford us the opportunity to relay our story to the scientific community, investors, and the public-at-large.”

For more news and information on MabCure Inc., please visit www.IRGnews.com/coi/MBCI where you can find a fact sheet on the company, investor presentations, and more.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website www.mabcure.com.

Forward-Looking Statement

This news release contains “forward-looking statements”. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024